Tag: share repurchase

BEIJING, June 05, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing over RMB40.6 million to repurchase 840,198 ordinary shares on June 4, 2026. With this latest repurchase, the Company has made over RMB1.67 billion in share repurchases year-to-date in 2026. This effort underscores the Company's ongoing commitment to delivering value to shareholders.

PETAH-TIKVA, Israel, June 04, 2026 (GLOBE NEWSWIRE) -- Global-e Online Ltd. (Nasdaq: GLBE), the platform powering global direct-to-consumer e-commerce, today announced that its Board of Directors (the "Board") has approved a “distribution”, as defined in the Israeli Companies Law, 5759-1999 (the “Companies Law”) by way of a share repurchase program, pursuant to which the Company may repurchase an aggregate amount of up to $500 million of its ordinary shares (the “Distribution”), subject to the completion of required Israeli regulatory procedures.

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Figure Technology Solutions (Nasdaq: FIGR; OPEN: FGRS), the leading blockchain-native capital marketplace for the origination, funding, sale, and trading of tokenized assets, today reported select preliminary operating data for the month ended May 31, 2026.

REYNOLDSBURG, Ohio, June 02, 2026 (GLOBE NEWSWIRE) -- Victoria’s Secret & Co. (“VS&Co” or the “Company”) (NYSE: VSXY) today reported financial results for the first quarter ended May 2, 2026.

Press Release

HOUSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Weatherford International plc (NASDAQ: WFRD) (“Weatherford” or the “Company”) filed its definitive proxy statement (the “Proxy Statement”) with the Securities and Exchange Commission (the “SEC”) on April 21, 2026, in connection with Weatherford’s proposal to Redomesticate from Ireland to the United States of America (the “U.S.”). Capitalized terms used herein but not defined have the meanings set forth in the Proxy Statement.

   
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial

More information:
Niina Ala-Luopa
+358 400 728 957, ir@vaisala.com